Advertisement

Impact of a Clinical Pharmacist Stress Ulcer Prophylaxis Management Program on Inappropriate Use in Hospitalized Patients

      Abstract

      Purpose

      Appropriate utilization of stress ulcer prophylaxis should be limited to high-risk, intensive care unit (ICU) patients. However, inappropriate stress ulcer prophylaxis use among all hospitalized patients remains a concern. The purpose of this study was to evaluate the clinical and economic impact of a novel pharmacist-managed stress ulcer prophylaxis program in ICU and general ward patients.

      Methods

      This retrospective, pre- and poststudy design was conducted in adult ICU and general ward patients at a large academic medical center between January 1, 2011 and January 31, 2012 to compare the rates of inappropriate stress ulcer prophylaxis before and after the implementation of a pharmacist-led stress ulcer prophylaxis management program.

      Results

      A total of 1134 unique patients consisting of 16,415 patient days were evaluated. The relative reduction in the rate of inappropriate stress ulcer prophylaxis days after program implementation in ICU and general ward patients was 58.3% and 83.5%, respectively (P < .001). The rates of ICU patients inappropriately continued on stress ulcer prophylaxis upon hospital discharge in the pre- and postimplementation groups were 29.9% and 3.6%, respectively (P < .001), whereas general ward patients significantly decreased from 36.2% to 5.4% in the pre- and postimplementation groups, respectively (P < .001). Total inpatient costs associated with all stress ulcer prophylaxis administered was $20,052.70 in the pre- and $3280.49 in the postimplementation group (P < .001), resulting in an estimated cost savings of > $200,000 annually. No differences in clinical outcomes were observed.

      Conclusions

      The implementation of a pharmacist-managed stress ulcer prophylaxis program was associated with a decrease in inappropriate acid suppression rates during hospitalization and upon discharge, as well as significant cost savings.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Allen M.E.
        • Kopp B.J.
        • Erstad B.L.
        Stress ulcer prophylaxis in the postoperative period.
        Am J Health Syst Pharm. 2004; 61: 588-596
        • Stollman N.
        • Metz D.C.
        Pathophysiology and prophylaxis of stress ulcer in intensive care unit patients.
        J Crit Care. 2005; 20: 35-45
        • Cook D.J.
        • Reeve B.K.
        • Guyatt G.H.
        • et al.
        Stress ulcer prophylaxis in critically ill patients: resolving discordant meta-analyses.
        JAMA. 1996; 275: 308-314
        • Cook D.
        • Guyatt G.
        • Marshall J.
        • et al.
        A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation.
        N Engl J Med. 1998; 338: 791-797
        • Lin P.C.
        • Chang C.H.
        • Hsu P.I.
        • Tseng P.L.
        • Huang Y.B.
        The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis.
        Crit Care Med. 2010; 38: 1197-1205
        • Marik P.E.
        • Vasu T.
        • Hirani A.
        • Pachinburavan M.
        Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis.
        Crit Care Med. 2010; 38: 2222-2228
        • Huang J.
        • Cao Y.
        • Liao C.
        • Wu L.
        • Gao F.
        Effect of histamine-2 receptor antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients: a meta-analysis of 10 randomized controlled trials.
        Crit Care. 2010; 14: R194
        • Dellinger R.P.
        • Levy M.M.
        • Rhodes A.
        • et al.
        Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock; 2012.
        Crit Care Med. 2013; 41: 580-637
        • American Society of Health-System Pharmacists
        ASHP therapeutic guidelines on stress ulcer prophylaxis.
        Am J Health Syst Pharm. 1999; 56: 347-379
      1. Guillamondegui OD, Gunter OL, Bonadies JA, et al. Practice management guidelines for stress ulcer prophylaxis: EAST Practice Management Guidelines Committee. Available at: www.east.org. Accessed June 16, 2014.

        • MacLaren R.
        • Campbell J.
        Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients.
        Crit Care Med. 2014; 42: 809-815
        • Estruch R.
        • Pedrol E.
        • Castells A.
        • Masanes F.
        • Marrades R.M.
        • Urbano-Marquez A.
        Prophylaxis of gastrointestinal tract bleeding with magaldrate in patients admitted to a general hospital ward.
        Scand J Gastroenterol. 1991; 26: 819-826
        • Grau J.M.
        • Casademont J.
        • Fernandez-Sola J.
        • Cardellach F.
        • Urbano-Marquez A.
        Prophylaxis of gastrointestinal tract bleeding in patients admitted to a general hospital ward. Comparative study of sucralfate and cimetidine.
        Scand J Gastroenterol. 1993; 28: 244-248
        • Qadeer M.A.
        • Richter J.E.
        • Brotman D.J.
        Hospital-acquired gastrointestinal bleeding outside the critical care unit: risk factors, role of acid suppression, and endoscopy findings.
        J Hosp Med. 2006; 1: 13-20
        • Pham C.Q.
        • Regal R.E.
        • Bostwick T.R.
        • Knauf K.S.
        Acid suppressive therapy use on an inpatient internal medicine service.
        Ann Pharmacother. 2006; 40: 1261-1266
        • Parente F.
        • Cucino C.
        • Gallus S.
        • et al.
        Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey.
        Aliment Pharmacol Ther. 2003; 17: 1503-1506
        • Thomas L.
        • Culley E.J.
        • Gladowski P.
        • Goff V.
        • Fong J.
        • Marche S.M.
        Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization.
        J Manag Care Pharm. 2010; 16: 122-129
        • Pillans P.I.
        • Kubler P.A.
        • Radford J.M.
        • Overland V.
        Concordance between proton pump inhibitors and prescribing guidelines.
        Med J Aust. 2000; 172: 16-18
        • Heidelbaugh J.J.
        • Inadomi J.M.
        Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients.
        Am J Gastroenterol. 2006; 101: 2200-2205
        • Wadibia E.C.
        • Lucas B.D.
        • Hilleman D.E.
        • Mooss A.N.
        Economic impact of inappropriate histamine2-receptor antagonist use.
        Clin Ther. 1997; 19: 1085-1091
        • Leheij R.J.
        • Sturkenboom M.C.
        • Hassing R.J.
        • Dieleman J.
        • Stricker B.H.
        • Jansen J.B.
        Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.
        JAMA. 2004; 292: 1955-1960
        • Eom C.S.
        • Jeon C.Y.
        • Lim J.W.
        • Cho E.G.
        • Park S.M.
        • Lee K.S.
        Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis.
        CMAJ. 2011; 183: 310-319
        • Cadle R.M.
        • Mansouri M.D.
        • Logan N.
        • Kudva D.R.
        • Musher D.M.
        Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis.
        Am J Health Syst Pharm. 2007; 64: 2359-2363
        • Dial S.
        • Delaney J.A.
        • Barkun A.N.
        • Suissa S.
        Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.
        JAMA. 2005; 294: 2989-2995
        • Howell M.D.
        • Novack V.
        • Grgurich P.
        • et al.
        Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection.
        Arch Intern Med. 2010; 170: 784-790
        • Linsky A.
        • Gupta K.
        • Lawler E.V.
        • Fonda J.R.
        • Hermos J.A.
        Proton pump inhibitors and risk for recurrent Clostridium difficile infection.
        Arch Intern Med. 2010; 170: 772-778
        • Lowe D.O.
        • Mamdani M.M.
        • Kopp A.
        • Low D.E.
        • Juurlink D.N.
        Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study.
        Clin Infect Dis. 2006; 43: 1272-1276
        • Heidelbaugh J.J.
        • Goldberg K.L.
        • Inadomi J.M.
        Over utilization of proton pump inhibitors: A review of cost-effectiveness and risk.
        Am J Gastroenterol. 2009; 104: S27-S32
        • Cote G.A.
        • Howden C.W.
        Potential adverse effects of proton pump inhibitors.
        Curr Gastroenterol Rep. 2008; 10: 208-214
        • Chen J.
        • Yuan Y.C.
        • Leontiadis G.I.
        • Howden C.W.
        Recent safety concerns with proton pump inhibitors.
        J Clin Gastroenterol. 2012; 46: 93-114
        • Grube R.R.
        • May D.B.
        Stress ulcer prophylaxis in hospitalized patients not in the intensive care units.
        Am J Health Syst Pharm. 2007; 64: 1396-1400
        • Priziola J.L.
        • Smythe M.A.
        • Dager W.E.
        Drug-induced thrombocytopenia in critically ill patients.
        Crit Care Med. 2010; 38: S145-S154
        • Cawley M.J.
        • Wittbrodt E.T.
        • Boyce E.G.
        • Skaar D.J.
        Potential risk factors associated with thrombocytopenia in a surgical intensive care unit.
        Pharmacotherapy. 1999; 19: 108-113
        • Wade E.E.
        • Rebuck J.A.
        • Healey M.A.
        • Rogers F.B.
        H2 antagonist-induced thrombocytopenia: is this a real phenomenon?.
        Intensive Care Med. 2002; 28: 459-465
        • Stephan F.
        • Hollande J.
        • Richard O.
        • Cheffi A.
        • Maier-Redelsperger M.
        • Flahault A.
        Thrombocytopenia in a surgical ICU.
        Chest. 1999; 115: 1363-1370
        • Cohen S.H.
        • Gerding D.N.
        • Johnson S.
        • et al.
        Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA).
        Infect Control Hosp Epidemiol. 2010; 31: 431-455
      2. 2012 Drug Topics Red Book. Medical Economics Company, Montvale, NJ2012
        • Tasaka C.L.
        • Burg C.
        • VanOsdol S.J.
        • et al.
        An interprofessional approach to reducing the overutilization of stress ulcer prophylaxis in adult medical and surgical intensive care units.
        Ann Pharmacother. 2014; 48: 462-469
        • Khalili H.
        • Dashti-Khavidaki S.
        • Hossein Talasaz A.H.
        • Tabeefar H.
        • Hendoiee N.
        Descriptive analysis of a clinical pharmacy intervention to improve the appropriate use of stress ulcer prophylaxis in a hospital infectious disease ward.
        J Manag Care Pharm. 2010; 16: 114-121
        • Hatch J.B.
        • Schulz L.
        • Fish J.T.
        Stress ulcer prophylaxis: Reducing non-indicated prescribing after hospital discharge.
        Ann Pharmacother. 2010; 44: 1565-1571
        • Hughes G.J.
        • Belgeri M.T.
        • Perry H.M.
        The impact of pharmacist interventions on the inapprorpriate use of acid-suppression therapy.
        Consult Pharm. 2011; 26: 485-490
        • Cook D.J.
        • Fuller H.D.
        • Guyatt G.H.
        • et al.
        Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group.
        N Engl J Med. 1994; 330: 377-381
        • Herzig S.J.
        • Howell M.D.
        • Ngo L.H.
        • Marcantonio E.R.
        Acid-suppressive medication use and the risk for hospital-acquired pneumonia.
        JAMA. 2009; 301: 2120-2128
        • MacLaren R.
        • Reynolds P.M.
        • Allen R.R.
        Histamine-2 receptor antagonists vs. proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit.
        JAMA Intern Med. 2014; 174: 564-574
        • Barletta J.F.
        • El-Ibiary S.Y.
        • Davis L.E.
        • Nguyen B.
        • Raney C.R.
        Proton pump inhibitors and the risk for hospital-acquired Clostridium difficile infection.
        Mayo Clin Proc. 2013; 88: 1085-1090